Orforglipron.
Orforglipron (brand: Foundayo, development code LY3502970) is a once-daily, orally administered GLP-1 receptor agonist developed by Eli Lilly.
Orforglipron (brand: Foundayo, development code LY3502970) is a once-daily, orally administered GLP-1 receptor agonist developed by Eli Lilly. Orforglipron is fda-approved, and PepCue grades its published evidence S tier (90/100). Also known as Foundayo, LY3502970. This is a research reference, not medical or dosing advice.
What it is
Orforglipron (brand: Foundayo, development code LY3502970) is a once-daily, orally administered GLP-1 receptor agonist developed by Eli Lilly. The FDA approved it on 1 April 2026 for chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity, alongside a reduced-calorie diet and increased physical activity. It is included on this site despite not being a peptide: orforglipron is a small-molecule, non-peptide agonist of the same receptor the injectable GLP-1 peptides target, and it is the closest direct alternative to them, so leaving it out would misrepresent the landscape people are actually choosing between.
How it works
Orforglipron binds and activates the GLP-1 receptor, the same class B G-protein-coupled receptor engaged by semaglutide, liraglutide and the GLP-1 arm of tirzepatide, producing glucose-dependent insulin secretion, slowed gastric emptying, suppressed glucagon and reduced appetite. The pharmacologically interesting part is how it does this without being a peptide. Work published in Science Translational Medicine (2024, PMID 39693407) characterises the basis for non-peptide agonism at this receptor: the molecule occupies a site that permits receptor activation from a small synthetic scaffold rather than mimicking the native hormone's full peptide sequence. Because it is not a peptide, it is not degraded in the gut the way oral peptide formulations are, which is why it can be taken as a conventional tablet with no food or water timing restrictions, unlike oral semaglutide.
The evidence
Human evidence is substantial and spans phase 2 through phase 3 in both obesity and type 2 diabetes. A phase 2 trial in adults with obesity (NEJM 2023, PMID 37351564) established dose-dependent weight reduction, and a parallel phase 2 programme in type 2 diabetes reported in The Lancet (2023, PMID 37369232) showed reductions in HbA1c and body weight. Phase 3 results in obesity were published in the New England Journal of Medicine (2025, PMID 40960239), and a separate NEJM report (2025, PMID 40544435) covered early type 2 diabetes. A head-to-head trial against oral semaglutide in adults with type 2 diabetes appeared in The Lancet (2026, PMID 41765029), and a randomized phase 3 maintenance trial was published in Nature Medicine (2026, PMID 42120723). ACHIEVE-5, adding orforglipron to titrated insulin glargine, was reported in JAMA (2026, PMID 42251769). This is a considerably more complete human evidence package than almost anything else discussed in peptide communities, which is the point worth taking from it.
The evidence, in brief
An oral, small-molecule, non-peptide GLP-1 receptor agonist from Eli Lilly, FDA-approved on 1 April 2026 as Foundayo for chronic weight management. In the 72-week phase 3 ATTAIN-1 trial in 3,127 adults with obesity, mean weight reduction was 11.2% at the highest dose versus 2.1% with placebo, and in the head-to-head ACHIEVE-3 trial in type 2 diabetes both doses tested were superior to oral semaglutide on HbA1c, with more gastrointestinal events and discontinuations. The human evidence is phase 3 and strong; what it lacks next to semaglutide is years of post-marketing experience.
- Wharton S et al.: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1)N Engl J Med, 2025 (PMID 40960239)
- Rosenstock J et al.: Once-daily oral orforglipron compared with oral semaglutide in type 2 diabetes (ACHIEVE-3)Lancet, 2026 (PMID 41765029)
- Foundayo (orforglipron): FDA prescribing informationFDA / DailyMed
Evidence maturity
An evidence-only reading: approval status, human vs preclinical data, mechanism and safety. Popularity never raises it. Research file #046
Approved or strong, consistent human evidence.
FDA-approved for a specific indication: the strongest lane.
Claim receipts
Popular claims about Orforglipron, checked against the state of the evidence. The verdict describes evidence maturity, never an invented study result.
The 72-week phase 3 ATTAIN-1 trial in adults with obesity found significantly greater weight reduction than placebo at every dose tested.
In a 52-week head-to-head trial in type 2 diabetes both doses tested were superior to oral semaglutide on HbA1c, but gastrointestinal events, discontinuations for adverse events and pulse-rate increases were also higher.
None of the published trials cited here compares it head to head with injectable semaglutide or tirzepatide for weight loss, and cross-trial percentage comparisons are not reliable.
It is a small-molecule, non-peptide agonist that reaches the same receptor as the peptides, which is why it is taken as an ordinary tablet with or without food.
Gastrointestinal events dominated the adverse-event profile and caused more discontinuations than placebo, and the label carries the class boxed warning on thyroid C-cell tumors.
Safety profile
The adverse-event profile reported across the trials is the familiar GLP-1 class pattern, dominated by gastrointestinal effects: nausea, vomiting, diarrhoea and constipation, generally most pronounced during dose escalation and often diminishing with time. Discontinuation for gastrointestinal reasons occurred in the trials. As an approved product it carries a prescribing label with the full contraindication and warning set for the GLP-1 receptor agonist class, and that label, not this page, is the authoritative safety document. Because it is a prescription medicine, safety monitoring happens through a prescriber rather than self-management, which is a meaningful difference from the research-use-only compounds elsewhere on this site.
Compound notes
- Orforglipron (Foundayo, development code LY3502970) is a small-molecule, non-peptide GLP-1 receptor agonist developed by Eli Lilly. It activates the same receptor as semaglutide and liraglutide without being a peptide.
- Pharmacology work in Science Translational Medicine (2024) describes it as a high-affinity, selective GLP-1 receptor ligand with low intrinsic efficacy and negligible beta-arrestin recruitment.
- Because it is a small, orally bioavailable molecule, it is taken as a once-daily film-coated tablet, with or without food, rather than injected.
- It was FDA-approved on 1 April 2026 for chronic weight management, after a phase 3 program spanning obesity (ATTAIN) and type 2 diabetes (ACHIEVE). In ATTAIN-1, mean weight reduction over 72 weeks was 11.2% at the highest dose tested versus 2.1% with placebo.
Both are daily GLP-1 tablets, but oral semaglutide is a peptide with strict empty-stomach and limited-water rules, while orforglipron is a small molecule taken with or without food. In the head-to-head ACHIEVE-3 trial in type 2 diabetes it lowered HbA1c more, with more gastrointestinal side effects and discontinuations.
In the phase 3b ATTAIN-MAINTAIN trial, people switched from injectable tirzepatide or semaglutide to orforglipron kept more of their prior weight reduction at 52 weeks than those switched to placebo, though not all of it.
- FDA-approved for chronic weight management only; an approval for that indication does not validate other uses.
- Adverse events in trials were predominantly gastrointestinal (nausea, vomiting, diarrhea, constipation), mostly mild to moderate and concentrated during dose escalation.
- The label carries the GLP-1 class boxed warning on thyroid C-cell tumors, and post-marketing experience is short because approval came in 2026. See the FDA label for the full warning set.
Regulatory status
FDA-approved 1 April 2026 as Foundayo (orforglipron) for chronic weight management in adults with obesity, or with overweight plus at least one weight-related comorbid condition, in combination with a reduced-calorie diet and increased physical activity. It is a prescription medicine. Approval is indication-specific: an approval for chronic weight management is not a validation of any other use it may be marketed or discussed for. Regulatory status elsewhere in the world varies and should be checked locally.
Approved by the FDA for at least one indication.
By the numbers
- 01FDA-approved 1 April 2026 as Foundayo for chronic weight management; developed by Eli Lilly.
- 02A small-molecule, non-peptide GLP-1 receptor agonist, not a peptide, despite acting on the same receptor as the injectable GLP-1 peptides.
- 03Taken orally once daily as a conventional tablet, with no food or water timing restrictions, unlike oral semaglutide.
- 04Phase 3 evidence published in NEJM, The Lancet, Nature Medicine and JAMA across obesity and type 2 diabetes.
- 05Prescription-only. Nothing on this page is a dose recommendation or a substitute for the prescribing label.
Orforglipron: research formats
Choose the format you are researching to see route-specific notes.
Once-daily film-coated tablet, taken with or without food. A small molecule, so there is nothing to inject or reconstitute.
Orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist approved by the FDA on 1 April 2026 as Foundayo and supplied as a film-coated tablet for oral use. Because it is an orally bioavailable small molecule rather than a peptide, it does not face the gut breakdown that limits oral peptide drugs. The label directs that it be taken once daily, with or without food, which is the practical difference from oral semaglutide (Rybelsus) and its empty-stomach, limited-water rules.
This page does not reproduce a dose or titration table for Foundayo. Dose selection and escalation follow the prescribing information and are a prescriber decision.
Gastrointestinal effects in the trials were concentrated during dose escalation, which is why the pace of escalation is managed by the prescriber rather than self-directed.
Orforglipron was developed and approved only as an oral tablet. There is no approved injectable or vial presentation, so anything sold in that form is not the approved medicine.
Sources
Every factual claim above resolves to a real, published source.
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity TreatmentNew England Journal of Medicine, 2025. Phase 3 obesity results. · randomized controlled trial · indexed →
- Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with ObesityNew England Journal of Medicine, 2023. Phase 2 obesity trial. · randomized controlled trial · indexed →
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 DiabetesNew England Journal of Medicine, 2025. · randomized controlled trial · indexed →
- Efficacy and safety of oral orforglipron in patients with type 2 diabetesThe Lancet, 2023. Multicentre phase 2 trial. · randomized controlled trial · indexed →
- Efficacy and safety of once-daily oral orforglipron compared with oral semaglutideThe Lancet, 2026. Head-to-head trial. · randomized controlled trial · indexed →
- Orforglipron for maintenance of body weight reductionNature Medicine, 2026. Double-blind randomized phase 3. · randomized controlled trial · indexed →
- Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: ACHIEVE-5JAMA, 2026. Randomized trial. · randomized controlled trial · indexed →
- The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipronScience Translational Medicine, 2024. · journal article · indexed →
See all 8 indexed papers for Orforglipron in the research library →
Cite this page
PepCue. “Orforglipron: the evidence.” PepCue, reviewed June 1, 2026. https://www.pepcue.app/p/orforglipron.
Log your doses, run the vial math, and keep a provider-ready record in PepCue.